179530 — ADBiotech Co Income Statement
0.000.00%
- KR₩20bn
- KR₩29bn
- KR₩11bn
Annual income statement for ADBiotech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9,815 | 11,840 | 10,632 | 10,472 | 11,136 |
Cost of Revenue | |||||
Gross Profit | 4,405 | 5,013 | 3,113 | 3,218 | 4,007 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 10,830 | 13,465 | 15,570 | 17,856 | 15,809 |
Operating Profit | -1,015 | -1,625 | -4,938 | -7,384 | -4,673 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7,476 | -2,415 | 2,696 | -5,457 | -9,013 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7,345 | -2,664 | 2,696 | -5,432 | -8,987 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -7,345 | -2,664 | 2,696 | -2,863 | -7,952 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -7,345 | -2,664 | 1,195 | -2,863 | -7,952 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,467 | -341 | 119 | -127 | -830 |
Dividends per Share |